drugset / Trial / NCT06829329

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

NCT06829329

Phase 2 Active not recruiting 105 enrolled Ausper Biopharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is to evaluate the efficacy and safety of AHB-137 in CHB participants. The total duration of the study, including screening phase, treatment phase and follow-up phase.

Timeline

Start
2024-12-13
Primary completion
2026-08-02
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AHB-137 Antisense oligonucleotide